Business Wire

Thales Wins Google Cloud Technology Partner of the Year Security – Data Protection Award

29.8.2023 17:00:00 EEST | Business Wire | Press release

Share

Thales has been selected as the Google Cloud Technology Partner of the Year in the Security – Data Protection category. Thales was selected alongside a global field of top Google Cloud partners for excellence in developing and implementing customer solutions based on Google Cloud’s technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230829348216/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

The Thales and Google Cloud collaboration addresses the needs of organizations around the world that are facing ever-increasing security, sovereignty, and performance requirements for their cloud deployments. With many years of cybersecurity expertise, Thales provides the level of trust and security required for customers around the world to move to the cloud, while maintaining the necessary level of control. By combining Thales’ platform expertise with Google Cloud’s enterprise-grade solutions and cutting-edge infrastructure, the two companies work closely on a number of broad data security initiatives.

Thales, in its constant search of excellence in its security portfolio, recently announced a new collaboration to develop data security capabilities and bring additional AI-powered features to users of its CipherTrust Data Security platform. This is powered by Google Cloud’s Vertex AI machine learning capabilities, to discover, classify and protect sensitive data in the cloud. The machine learning functionality helps to automate fundamental tasks for customers and ensure their sensitive cloud-hosted data remains protected.

Since late 2022, Thales’ CipherTrust Cloud Key Manager has also supported Bring Your Own Key (BYOK) initiatives, including those for Google Cloud and Google Workspace. Thales and Google Cloud have also collaborated to operate a sovereign cloud joint venture (S3NS) for Google Cloud customers in France who seek to meet stringent data sovereignty requirements, such as those applicable to state and critical infrastructure organizations.

Thales has built a structured cloud offering for companies that want to meet the most demanding data protection standards. In France, S3NS, the joint venture between Thales and Google Cloud, aims to offer French companies and public institutions a solution providing the equivalent of Google Cloud , compliant with the “SecNumCloud” label, a certification from the French information systems security agency (ANSSI). To date, SecNumCloud has the highest level of protection in France, excluding the protection of national defense secrets, and in Europe. S3NS has a first offering already available that offers additional guarantees & controls, such as data location in Europe and external encryption managed by S3NS (based on Thales technology).

“Google Cloud’s partner awards recognize the significant impact and customer success that our partners have driven over the past year," said Kevin Ichhpurani, Corporate Vice President, Global Ecosystem and Channels at Google Cloud. "We're delighted to recognize Thales as a 2023 Google Cloud Partner Award winner, and look forward to a continued strong partnership in support of our mutual customers."

Sebastien Cano, Senior Vice President of Cloud Protection and Licensing activities at Thales, commented: “We are very proud of our ongoing relationship with Google Cloud and this latest award recognises the brilliant work we’ve been doing with them across a range of projects. Together we are helping customers around the world discover, classify and protect their data more efficiently, and ensure their move to the cloud is as secure and compliant as possible.”

Thales is also participating at Google Cloud Next, which is taking place from 29-31 August 2023. Some of the sessions include:

How global leaders are addressing digital sovereignty requirements, with Cyprien Falque, CEO of S3NS More details about the event, which will be available to watch both live and on-demand online, can be found here.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

 

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

 

Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

 

PLEASE VISIT

Thales Group
Cloud Protection & Licensing Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye